Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists

KALV - KalVista Pharmaceuticals Inc Stock Price, Fair Value and News

$12.61+0.36 (+2.94%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

KALV Price Action

Last 7 days

7.2%

Last 30 days

35.5%

Last 90 days

42.4%

Trailing 12 Months

-0.3%

KALV RSI Chart

JunJulAugSepOctNovDec2025FebMar102030405060708090

KALV Valuation

Market Cap

619.0M

Price/Earnings (Trailing)

-3.52

Price/Sales (Trailing)

12.38

EV/EBITDA

-3.61

Price/Free Cashflow

-4.84

KALV Price/Sales (Trailing)

20222023202420251020304050

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

KALV Fundamentals

KALV Revenue

Revenue (TTM)

50.0M

201420162018202020222024010M20M30M40M50M

KALV Earnings

Earnings (TTM)

-175.9M

Earnings Growth (Yr)

-67.11%

Earnings Growth (Qtr)

-14.77%

201420162018202020222024-150M-100M-50M0

KALV Profitability

EBT Margin

-253.29%

Return on Equity

-121.18%

Return on Assets

-63.72%

Free Cashflow Yield

-20.65%

KALV Investor Care

Shares Dilution (1Y)

17.84%

Diluted EPS (TTM)

-3.76

KALV Alerts

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
201420162018202020222024010M20M30M40M50M
Net sales
YearQ1Q2Q3Q4
2024050.0M00
202011.8M12.7M00
201918.0M16.1M15.8M14.1M
20183.7M8.4M12.0M16.5M
20171.6M1.5M655.0K1.6M
201602.1M1.9M1.7M
2015916.5K1.8M00
2014318.5K222.0K125.5K29.0K
2013000415.0K
Get all data in R, Python etc through our Historical Stock Data APIs

About KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEkalvista.com
 SECTORHealthcare
 INDUSTRYBiotechnology
 EMPLOYEES118

KalVista Pharmaceuticals Inc Frequently Asked Questions

What is the ticker symbol for KalVista Pharmaceuticals Inc? What does KALV stand for in stocks?

KALV is the stock ticker symbol of KalVista Pharmaceuticals Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of KalVista Pharmaceuticals Inc (KALV)?

As of Wed Mar 12 2025, market cap of KalVista Pharmaceuticals Inc is 618.96 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of KALV stock?

You can check KALV's fair value in chart for subscribers.

Is KalVista Pharmaceuticals Inc a good stock to buy?

The fair value guage provides a quick view whether KALV is over valued or under valued. Whether KalVista Pharmaceuticals Inc is cheap or expensive depends on the assumptions which impact KalVista Pharmaceuticals Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for KALV.

What is KalVista Pharmaceuticals Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Mar 12 2025, KALV's PE ratio (Price to Earnings) is -3.52 and Price to Sales (PS) ratio is 12.38. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. KALV PE ratio will change depending on the future growth rate expectations of investors.